McDermott Advises Acticor Biotech on Development of Emergency Treatment for Ischemic Stroke

Überblick


PARIS (02 February 2015) — Acticor Biotech, a biotech company dedicated to the development of an emergency treatment of ischemic stroke, announced on 26 January the successful closing of its first capital increase for a total of €590,000.

This amount, raised from investors of the crowdfunding platform Anaxago and Business Angels, enables the young Inserm (French National Institute of Health and Medical Research) spin-off to launch the development of its product. The drug candidate ACT-017 is a humanized antibody (Fab) directed against a new target of major interest for the treatment of cerebral stroke, the platelet glycoprotein VI (GPVI).

With two thirds of the capital increase raised with the equity crowdfunding platform Anaxago, Acticor Biotech becomes one of the first companies to successfully raise equity crowd-funds for therapeutic biotechnologies. The level of investors’ interest in this project demonstrates the strong will of participants to support the development of innovative solutions addressing major public health concerns.

This capital increase takes place as Acticor just signed an agreement with Genopole that will allow the company to join the biocluster and benefit from services to support its structural development and growth.

For the crowdfunding platform Anaxago, the funding of a first biotech startup further validates the business model for the healthcare sector.

The Paris office of McDermott Will & Emery (Emmanuelle Trombe, Anthony Paronneau, Kamal Naffi and Mathilde Peschard) advised Acticor Biotech on this operation. Anaxago was advised by Kopelman & Seletzky (Eric Kopelman).

About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.